Aptus Capital Advisors, LLC

Source: SEC Form 13F · as of Mar 2026

Aptus Capital Advisors, LLC holds 44 biotech & pharma companies tracked by BioSniper, totaling $274.4M in value as of Mar 2026 (SEC Form 13F).

Companies held

44

Total value held

$274.4M

CompanySharesValue
LLYELI LILLY & Co52,722$48.5M
JNJJOHNSON & JOHNSON193,144$47.2M
ABBVAbbVie Inc.134,719$29.3M
MRKMerck & Co., Inc.192,739$23.2M
ABTABBOTT LABORATORIES161,380$16.6M
UNHUnitedHealth Group Incorporated Common Stock (DE)57,798$15.6M
AMGNAMGEN INC41,466$14.6M
GILDGILEAD SCIENCES, INC.75,380$10.5M
PFEPFIZER INC358,846$10.1M
MCKMcKesson Corporation10,316$8.9M
BMYBRISTOL MYERS SQUIBB CO143,031$8.7M
VRTXVERTEX PHARMACEUTICALS INC / MA14,644$6.5M
IDXXIDEXX LABORATORIES INC /DE10,097$5.7M
PMPhilip Morris International Inc34,152$5.6M
OCULOCULAR THERAPEUTIX, INC529,779$4.5M
ELVElevance Health Inc.9,730$2.8M
ZTSZoetis Inc.21,756$2.6M
NVSNovartis AG15,944$2.4M
CORCencora Inc.5,142$1.6M
CAHCardinal Health Inc.6,363$1.3M
RPRXRoyalty Pharma plc21,335$1.0M
REGNREGENERON PHARMACEUTICALS, INC.1,264$977K
GMOptec International, Inc.11,100$827K
ZBHZimmer Biomet Holdings Inc.6,117$553K
AZNASTRAZENECA PLC2,590$511K
ALNYALNYLAM PHARMACEUTICALS, INC.1,513$501K
NVONovo Nordisk A/S11,710$430K
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)7,241$400K
MISTMilestone Pharmaceuticals Inc.280,250$333K
GEHCGE HealthCare Technologies Inc.3,931$280K
INCYIncyte Corp.2,794$263K
UTHRUNITED THERAPEUTICS Corp415$246K
NBIXNEUROCRINE BIOSCIENCES INC1,814$239K
BIIBBIOGEN INC.1,288$236K
ROIVRoivant Sciences Ltd.8,118$225K
BAXBaxter International Inc.10,916$183K
PGENPRECIGEN, INC.44,428$172K
DRTSAlpha Tau Medical Ltd.20,000$141K
VTRSViatris Inc10,101$136K
NTLAIntellia Therapeutics, Inc.10,278$132K
ALTSALT5 Sigma Corp90,195$100K
EPRXEUPRAXIA PHARMACEUTICALS INC.10,500$76K
PLXProtalix BioTherapeutics, Inc.27,231$59K
TNYATenaya Therapeutics, Inc.12,065$8K

13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.